Figure 1.
Probability of a) treatment discontinuation; b) virological failure at 6 and 12 months of patients treated with co-formulated rilpivirine/emtricitabine/tenofovir for treatment simplification.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.